STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Urology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2012.09.052PMID 23063454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

  2012cited by this paper
• Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

  2011cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

  2010cited by this paper
• Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.

  2010cited by this paper
• A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

  2010cited by this paper
• Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment

  2007cited by this paper
• Prevalence of renal cell carcinoma: A nation‐wide survey in Japan, 2002

  2007cited by this paper
• Copy-number variation and association studies of human disease

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells1

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.

  2007influential reference
• Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1

  2006cited by this paper
• RECIST revisited: a review of validation studies on tumour assessment.

  2006cited by this paper
• The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

  2006cited by this paper
• Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein

  2005cited by this paper
• Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

  2005influential reference
• Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

  2005cited by this paper
• The STATs of cancer — new molecular targets come of age

  2004cited by this paper
• Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

  2004cited by this paper
• Signal Transducer and Activator of Transcription 3 Is the Dominant Mediator of the Anti-Inflammatory Effects of IL-10 in Human Macrophages

  2004cited by this paper
• Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma

  2003cited by this paper
• A comprehensive review of genetic association studies

  2002cited by this paper
• Genotyping single-nucleotide polymorphisms by the invader assay with dual-color fluorescence polarization detection.

  2001cited by this paper
• STAT family of transcription factors in cytokine-mediated biological responses.

  2000cited by this paper
• STATs in oncogenesis

  2000cited by this paper
• STATs and gene regulation.

  1997cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper

• Allosteric inhibition of the tyrosine phosphatase SHP2 enhances the anti-tumor immunity of interferon α through induction of caspase-1-mediated pyroptosis in renal cancer.

  2024cites this paper
• Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

  2023cites this paper
• Genetics and Functional Mechanisms of STAT3 Polymorphisms in Human Tuberculosis

  2021cites this paper
• Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer

  2020cites this paper
• The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review

  2019cites this paper
• The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review.

  2019cites this paper
• Title Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy

  2019cites this paper
• Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma

  2018cites this paper
• Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.

  2018cites this paper
• STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population

  2016cites this paper
• Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients

  2016cites this paper
• The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference.

  2016cites this paper
• Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy

  2016cites this paper
• STAT3 polymorphisms may predict an unfavorable response to first‐line platinum‐based therapy for women with advanced serous epithelial ovarian cancer

  2016cites this paper
• Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma

  2016cites this paper
• Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

  2015cites this paper
• STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.

  2015cites this paper
• Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder.

  2015cites this paper
• Association of Single Nucleotide Polymorphism rs1053004 in Signal Transducer and Activator of Transcription 3 (STAT3) with Susceptibility to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.

  2015cites this paper
• Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

  2015cites this paper
• Therapeutic Alpha-Interferons Protein: Structure, Production, and Biosimilar

  2015cites this paper
• Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model

  2015cites this paper
• STAT 3 and STAT 5 b polymorphism contributes to breast cancer risk and clinical outcomes

  2015cites this paper
• Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy

  2015cites this paper
• Trial watch

  2014cites this paper
• Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.

  2014cites this paper
• Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis.

  2014cites this paper
• Small molecule compounds targeting DNA binding domain of STAT3 for inhibition of tumor growth and metastasis

  2014cites this paper
• Phosphorylated signal transducer and activator of transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.

  2014cites this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cites this paper
• Recent advances in the treatment of metastatic renal cell carcinoma

  2013cites this paper
• Cytokines in the Management of Advanced Renal Cell Cancer

  2012cites this paper